Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB	Actinomycetales infectious disease, Bacterial Infections and Mycoses, Infections, bacterial infectious disease, gram-positive bacterial infections, lung disorder, mycobacterial infectious disease, pulmonary tuberculosis, respiratory system disorder, respiratory tract infectious disorder, tuberculosis	Not yet recruiting	Phase 2	2026-08-24		NCT06205589

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	5
National Institute of Allergy and Infectious Diseases (NIAID)	402

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.